Coslada

Researchers are evaluating the safety, feasibility, and initial effectiveness of using expanded allogeneic mesenchymal stem cells derived from adipose tissue (HC106) to treat urinary incontinence in women over 50 years old. This phase I controlled trial aims to provide proof of concept and preliminary efficacy data by comparing the stem cell treatment to a saline placebo control group. The study focuses on women diagnosed with genuine or mixed stress urinary incontinence who have not responded to or refused rehabilitative or surgical treatments. Participants are divided into two groups: one receiving a single dose of 40 million HC106 cells and the other receiving a placebo saline solution. The treatment involves anesthesia, identification of the urinary sphincter area through cystoscopy, and injection of the cell suspension or placebo at two specific points around the sphincter. The injection is shallow to create a visible wheal, and any remaining cells or materials are properly discarded following hospital waste procedures. Throughout the study, patients will be monitored for complications and safety within 7 days following treatment. Researchers will assess the proportion of patients experiencing any treatment-related complications. Participants must provide informed consent and undergo urine cultures to ensure no active infection at enrollment. The overall study duration and additional long-term follow-up details are not specified but safety and initial efficacy outcomes will be closely observed during the trial period.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are evaluating the effects of 12 months of continuous positive airway pressure (CPAP) treatment combined with conventional drug therapy on the lipid profile and other health markers in patients aged 35 to 80 years with moderate to severe obstructive sleep apnea (OSA) and dyslipidemia. This Phase IV randomized, open-label, parallel clinical trial aims to determine if CPAP can improve cholesterol levels, uric acid concentration, insulin resistance, cardiovascular risk, glycemic control, inflammation, oxidative stress, sympathetic activity, appetite-regulating hormones, and quality of life in this population. Participants are randomly assigned to one of two groups: one receiving conventional hygienic-dietary recommendations and promotion of daily physical activity, and the other receiving the same conventional treatment plus CPAP therapy. CPAP treatment starts at a pressure of 8 cmH2O and is adjusted within three weeks using automatic titration to the pressure at the 95th percentile. The conventional treatment includes guidance on sleep hygiene and encouragement to walk 10,000 steps daily, monitored with a pedometer and step diary reviewed at each visit. During the study, participants undergo regular assessments including lipid profiles, uric acid, blood glucose, HbA1c, creatinine, C-reactive protein, and various systemic biomarkers related to inflammation, oxidative stress, endothelial damage, sympathetic activity, and appetite regulation. Clinical questionnaires evaluating quality of life and physical activity are also completed. Safety is monitored through adverse event reporting, CPAP compliance tracking, sleepiness questionnaires, and monitoring for cardiovascular events. The study enrolls about 110 patients per group and measures outcomes over a 12-month treatment period.

Researchers are investigating the effects of different doses of dexamethasone, a corticosteroid, in adults with acute hypoxemic respiratory failure (AHRF) caused by infections, including COVID-19. This condition ranges from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The trial aims to clarify whether moderate doses of dexamethasone reduce mortality more than low doses in patients requiring mechanical ventilation in intensive care units. Participants will be randomly assigned to receive intravenous dexamethasone either at a low dose of 6 mg per day for 10 days or a higher dose regimen of 20 mg per day for 5 days followed by 10 mg per day for another 5 days. This is a randomized, controlled, open-label study conducted across multiple centers in Spain. The study focuses on patients who are mechanically ventilated with confirmed pulmonary or systemic infections causing AHRF or ARDS. During the study, researchers will monitor patients for 60-day mortality as the main outcome and assess the number of days they are free from mechanical ventilation within 28 days. The study follows the intention-to-treat principle, ensuring all randomized patients are analyzed according to their assigned treatment. The trial includes detailed clinical assessments, chest imaging, and oxygenation measurements as part of patient evaluation throughout the treatment period.